A 45-year-old woman with a history of diffuse cutaneous systemic sclerosis is evaluated in the clinic for worsening episodes of painful digital color changes (white to blue to red) triggered by cold exposure. She currently takes no medications for this issue. Arrange the following interventions in the most appropriate stepwise escalation sequence for managing her Raynaud phenomenon, starting with the initial management step and progressing to therapies for refractory, severe disease with impending digital ischemia.
- 1Conservative measures (e.g., cold avoidance, core warming, smoking cessation)
- 2Oral dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine)
- 3Oral phosphodiesterase-5 inhibitors (e.g., sildenafil)
- 4Intravenous prostanoids (e.g., epoprostenol) or endothelin receptor antagonists
Answer
The correct sequence for managing Raynaud phenomenon escalates from conservative measures to calcium channel blockers, then to phosphodiesterase-5 inhibitors, and finally to intravenous prostanoids for severe disease.
The management of Raynaud phenomenon is step-wise. It begins universally with lifestyle modifications (cold avoidance, smoking cessation). If symptoms persist, first-line pharmacologic therapy is an oral dihydropyridine calcium channel blocker (e.g., amlodipine). If still refractory, a phosphodiesterase-5 inhibitor (e.g., sildenafil) is typically added. For severe, refractory cases presenting with critical digital ischemia or active digital ulcers, intravenous prostanoids (e.g., epoprostenol) or endothelin receptor antagonists (e.g., bosentan) are indicated.
Step-by-Step Solution
Key Concept
Management of secondary Raynaud phenomenon follows a step-wise escalation from conservative lifestyle measures to oral vasodilators (starting with calcium channel blockers), followed by advanced therapies (like IV prostanoids) for refractory ischemic complications.